全文获取类型
收费全文 | 55492篇 |
免费 | 2886篇 |
国内免费 | 408篇 |
专业分类
耳鼻咽喉 | 627篇 |
儿科学 | 1188篇 |
妇产科学 | 1705篇 |
基础医学 | 6759篇 |
口腔科学 | 2002篇 |
临床医学 | 4297篇 |
内科学 | 15137篇 |
皮肤病学 | 1125篇 |
神经病学 | 4854篇 |
特种医学 | 1427篇 |
外科学 | 8441篇 |
综合类 | 208篇 |
一般理论 | 13篇 |
预防医学 | 3205篇 |
眼科学 | 930篇 |
药学 | 3091篇 |
中国医学 | 162篇 |
肿瘤学 | 3615篇 |
出版年
2023年 | 340篇 |
2022年 | 739篇 |
2021年 | 1688篇 |
2020年 | 924篇 |
2019年 | 1328篇 |
2018年 | 1806篇 |
2017年 | 1205篇 |
2016年 | 1298篇 |
2015年 | 1564篇 |
2014年 | 2144篇 |
2013年 | 2774篇 |
2012年 | 4231篇 |
2011年 | 4217篇 |
2010年 | 2328篇 |
2009年 | 2029篇 |
2008年 | 3671篇 |
2007年 | 3752篇 |
2006年 | 3566篇 |
2005年 | 3510篇 |
2004年 | 3177篇 |
2003年 | 2886篇 |
2002年 | 2608篇 |
2001年 | 629篇 |
2000年 | 577篇 |
1999年 | 596篇 |
1998年 | 474篇 |
1997年 | 402篇 |
1996年 | 374篇 |
1995年 | 355篇 |
1994年 | 287篇 |
1993年 | 230篇 |
1992年 | 323篇 |
1991年 | 260篇 |
1990年 | 244篇 |
1989年 | 192篇 |
1988年 | 175篇 |
1987年 | 173篇 |
1986年 | 153篇 |
1985年 | 139篇 |
1984年 | 126篇 |
1983年 | 110篇 |
1982年 | 131篇 |
1981年 | 101篇 |
1980年 | 94篇 |
1979年 | 69篇 |
1978年 | 70篇 |
1977年 | 59篇 |
1976年 | 54篇 |
1974年 | 54篇 |
1973年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
2.
3.
4.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
5.
6.
7.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
8.
9.
10.